Cargando…
Low levels of tumor suppressor candidate 3 predict poor prognosis of patients with hepatocellular carcinoma
PURPOSE: The tumor suppressor candidate 3 (TUSC3) has been considered to be closely associated with the occurrence, development and invasion of various malignant tumors. However, the expression of TUSC3 in hepatocellular carcinoma (HCC) tissues remains ambiguous. The purpose of this research was to...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5825997/ https://www.ncbi.nlm.nih.gov/pubmed/29503566 http://dx.doi.org/10.2147/OTT.S153381 |
_version_ | 1783302272444268544 |
---|---|
author | Sheng, Xu-Ren Xing, Song-Ge Wang, Run-Dong Chen, Kang Jia, Wei-Dong |
author_facet | Sheng, Xu-Ren Xing, Song-Ge Wang, Run-Dong Chen, Kang Jia, Wei-Dong |
author_sort | Sheng, Xu-Ren |
collection | PubMed |
description | PURPOSE: The tumor suppressor candidate 3 (TUSC3) has been considered to be closely associated with the occurrence, development and invasion of various malignant tumors. However, the expression of TUSC3 in hepatocellular carcinoma (HCC) tissues remains ambiguous. The purpose of this research was to investigate the expression of TUSC3 in HCC tissues and analyze the relationship between TUSC3 levels and clinicopathological characteristics and prognosis of HCC patients. MATERIALS AND METHODS: Immunohistochemistry was used to detect the expression of TUSC3 in HCC and the corresponding para-cancerous tissues from 92 samples of HCC patients. mRNA and protein expression levels of TUSC3 were evaluated by quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot assays in 25 paired HCC and corresponding adjacent nontumor tissues. Furthermore, statistical analysis was applied to evaluate the correlation between TUSC3 level and the clinicopathological features and prognosis of HCC patients. RESULTS: Immunohistochemical assay indicated that the expression of TUSC3 was significantly lower in HCC tissues when compared with the corresponding para-cancerous tissues (χ(2)=11.512, P=0.001). The analysis of clinicopathological characteristics showed that low expression of TUSC3 in HCC tissues was significantly associated with Edmondson grade, Barcelona Clinic Liver Cancer stage and tumor size (P=0.008, 0.009 and 0.020, respectively). Univariate analysis showed that the expression of TUSC3 was strongly correlated with overall survival (OS) and disease-free survival (DFS) after radical surgery in HCC patients (P<0.001, P<0.001, respectively). Multivariate analysis revealed that the TUSC3 level was an independent risk factor for OS and DFS in HCC patients (P=0.001, P<0.001, respectively). Results of qRT-PCR and Western blot assays indicated that the level of TUSC3 in HCC tissues was significantly lower than that in the corresponding adjacent noncancerous tissues (P<0.01, P<0.001). CONCLUSION: The expression of TUSC3 in HCC was significantly downregulated and was correlated with tumor progression and prognosis, which could be used as an independent predictor of prognosis in HCC patients. |
format | Online Article Text |
id | pubmed-5825997 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-58259972018-03-02 Low levels of tumor suppressor candidate 3 predict poor prognosis of patients with hepatocellular carcinoma Sheng, Xu-Ren Xing, Song-Ge Wang, Run-Dong Chen, Kang Jia, Wei-Dong Onco Targets Ther Original Research PURPOSE: The tumor suppressor candidate 3 (TUSC3) has been considered to be closely associated with the occurrence, development and invasion of various malignant tumors. However, the expression of TUSC3 in hepatocellular carcinoma (HCC) tissues remains ambiguous. The purpose of this research was to investigate the expression of TUSC3 in HCC tissues and analyze the relationship between TUSC3 levels and clinicopathological characteristics and prognosis of HCC patients. MATERIALS AND METHODS: Immunohistochemistry was used to detect the expression of TUSC3 in HCC and the corresponding para-cancerous tissues from 92 samples of HCC patients. mRNA and protein expression levels of TUSC3 were evaluated by quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot assays in 25 paired HCC and corresponding adjacent nontumor tissues. Furthermore, statistical analysis was applied to evaluate the correlation between TUSC3 level and the clinicopathological features and prognosis of HCC patients. RESULTS: Immunohistochemical assay indicated that the expression of TUSC3 was significantly lower in HCC tissues when compared with the corresponding para-cancerous tissues (χ(2)=11.512, P=0.001). The analysis of clinicopathological characteristics showed that low expression of TUSC3 in HCC tissues was significantly associated with Edmondson grade, Barcelona Clinic Liver Cancer stage and tumor size (P=0.008, 0.009 and 0.020, respectively). Univariate analysis showed that the expression of TUSC3 was strongly correlated with overall survival (OS) and disease-free survival (DFS) after radical surgery in HCC patients (P<0.001, P<0.001, respectively). Multivariate analysis revealed that the TUSC3 level was an independent risk factor for OS and DFS in HCC patients (P=0.001, P<0.001, respectively). Results of qRT-PCR and Western blot assays indicated that the level of TUSC3 in HCC tissues was significantly lower than that in the corresponding adjacent noncancerous tissues (P<0.01, P<0.001). CONCLUSION: The expression of TUSC3 in HCC was significantly downregulated and was correlated with tumor progression and prognosis, which could be used as an independent predictor of prognosis in HCC patients. Dove Medical Press 2018-02-21 /pmc/articles/PMC5825997/ /pubmed/29503566 http://dx.doi.org/10.2147/OTT.S153381 Text en © 2018 Sheng et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Sheng, Xu-Ren Xing, Song-Ge Wang, Run-Dong Chen, Kang Jia, Wei-Dong Low levels of tumor suppressor candidate 3 predict poor prognosis of patients with hepatocellular carcinoma |
title | Low levels of tumor suppressor candidate 3 predict poor prognosis of patients with hepatocellular carcinoma |
title_full | Low levels of tumor suppressor candidate 3 predict poor prognosis of patients with hepatocellular carcinoma |
title_fullStr | Low levels of tumor suppressor candidate 3 predict poor prognosis of patients with hepatocellular carcinoma |
title_full_unstemmed | Low levels of tumor suppressor candidate 3 predict poor prognosis of patients with hepatocellular carcinoma |
title_short | Low levels of tumor suppressor candidate 3 predict poor prognosis of patients with hepatocellular carcinoma |
title_sort | low levels of tumor suppressor candidate 3 predict poor prognosis of patients with hepatocellular carcinoma |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5825997/ https://www.ncbi.nlm.nih.gov/pubmed/29503566 http://dx.doi.org/10.2147/OTT.S153381 |
work_keys_str_mv | AT shengxuren lowlevelsoftumorsuppressorcandidate3predictpoorprognosisofpatientswithhepatocellularcarcinoma AT xingsongge lowlevelsoftumorsuppressorcandidate3predictpoorprognosisofpatientswithhepatocellularcarcinoma AT wangrundong lowlevelsoftumorsuppressorcandidate3predictpoorprognosisofpatientswithhepatocellularcarcinoma AT chenkang lowlevelsoftumorsuppressorcandidate3predictpoorprognosisofpatientswithhepatocellularcarcinoma AT jiaweidong lowlevelsoftumorsuppressorcandidate3predictpoorprognosisofpatientswithhepatocellularcarcinoma |